3D Drug delivery

To drive the nanomedicine field forward to yield pharmaceutical products profitable for society, the fullest consideration should be given to the greater involvement of industrial, translational, and clinical scientists in current nanomedicinal research. This programme is at the forefront of national pharmaceutical nanomedicine research, and will undoubtedly contribute to intensified structural collaboration between academia, industry, and clinic.

Nanomedicines will be developed with broad applicability to disease treatment, as exemplified by the choice for projects studying the applicability of nanomedicines for the treatment of cancer, rheumatoid arthritis, diabetic nephropathy, end-stage renal disease, cardiovascular disease, sclerotic diseases, and tuberculosis. The programme is innovative, multidisciplinary with clear potential to deliver nanomedicines to the clinic and the market, as reflected by the large involvement of industry (mainly by SME’s), clinical and translational scientists, and clinical proof-of-concept studies.

Back to theme 3: Nanomedicine

Foto: Bram Saeys. 9-6-2011, STW NanoNext Karel V Utrecht

Programme Director:
Prof. dr. Gert Storm (University of Twente)